Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SoFT - Sevelamer on FGF23 Trial
NL-OMON41487Phase 4Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2014
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sevelamer carbonate in chronic kidney disease (CKD), sponsored by Vrije University Medical Center. Primary endpoint: Change in C-terminal FGF-23 at highest sevelamer dose versus baseline. Started Feb 2014; status: active, not recruiting.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON41487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41487.